FGFR2/3 Inhibitor Composition for Lower On-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pan-FGFR inhibitors exhibit on-target toxicities, including FGFR1-mediated dose-limiting toxicities and FGFR4-mediated dose-limiting toxicity, necessitating the development of next-generation dual FGFR2/3 inhibitors with higher selectivity for cancer treatment.
Innovation Solution
Development of compounds of Formula (I) and their pharmaceutically acceptable salts or stereoisomers, which selectively inhibit FGFR2 and FGFR3, reducing off-target effects and enhancing therapeutic efficacy in cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-FGFR inhibitors are used to achieve broad FGFR coverage, then clinical responses are achieved, but on-target toxicities occur including hyperphosphatemia and diarrhea
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures that selectively target FGFR2 and FGFR3 subtypes while sparing FGFR1 and FGFR4. The compounds feature distinct structural motifs (e.g., heterocyclic rings, specific substituent patterns) that create subtype-specific binding affinity, allowing therapeutic action on cancer-relevant FGFR subtypes without activating toxic pathways mediated by other subtypes.
Solution Approach 2:
The patent segments the FGFR target family by developing inhibitors that specifically bind to FGFR2 and FGFR3 while excluding FGFR1 and FGFR4. This segmentation is achieved through structure-activity relationship optimization where specific molecular features (such as R1-R15 substituents, heterocyclic core structures) confer selectivity for particular FGFR subtypes, dividing the broad FGFR inhibition into targeted subtype-specific inhibition.
2Reliability
If FGFR1 is inhibited to achieve anti-cancer effect, then tumor growth is suppressed, but dose-limiting toxicities occur
Solution Approach 1:
The patent extracts the toxic FGFR1 inhibition function from the therapeutic FGFR2/3 inhibition function. By designing compounds with molecular structures that specifically exclude FGFR1 binding (through absence of FGFR1-binding motifs and presence of FGFR2/3-selective features), the invention removes the harmful FGFR1-mediated toxicities while preserving the desired anti-cancer activity through FGFR2/3 inhibition.
3Reliability
If FGFR4 is inhibited to achieve anti-cancer effect, then tumor progression is controlled, but dose-limiting diarrhea occurs
Solution Approach 1:
The patent applies local quality by incorporating molecular features that create selective binding to FGFR4 while maintaining FGFR2/3 inhibition. Specific substituent patterns (R1-R15 groups), heterocyclic core structures, and spatial arrangements are optimized to achieve subtype-selective engagement, allowing therapeutic FGFR4 inhibition without triggering the diarrhea-mediated toxicities associated with broader FGFR family inhibition.
4Adaptability or versatility
If broad FGFR inhibition is achieved, then multiple cancer types are treated, but selectivity against FGFR1 is reduced
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular parameters (substituent types R1-R15, heterocyclic core structures, bond lengths, spatial configurations) to tune the selectivity profile. By adjusting these chemical parameters, the compounds achieve enhanced FGFR1 selectivity while maintaining broad cancer type applicability through FGFR2/3/4 inhibition, effectively decoupling selectivity from versatility.
Data Source
AI summary
Provided are FGFR2 and FGFR3 inhibitors of Formula (I) and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with FGFR2 and/or FGFR3.